Navigation Links
Autoimmune Response in Multiple Sclerosis

In multiple sclerosis (MS), the myelin that surrounds the axons of nerve cells is attacked by the bodys own T cells, resulting in slowed and disrupted nerve impulses and, ultimately, axon loss .

Myelin basic protein (MBP) is a major component of the myelin sheath and when used as an antigen will induce experimental autoimmune encephalitis (EAE) in mice, which is used as an animal model of human MS.

Interestingly, myelin-specific T cells are found in both healthy individuals as well as patients with MS, thus researchers have been working to determine what specific characteristic of these destructive T cells is dominant in driving the development of EAE/MS.

In a study appearing online on July 12 in advance of publication in the August print issue of the Journal of Clinical Investigation, Eli Sercarz and colleagues from the Torrey Pines Institute for Molecular Studies immunized mice with an epitope of MBP known as Ac19, which resulted in a single episode of EAE in these animals, followed by recovery and resistance to any reinduction of disease.

The authors then went on to characterize the Ac19specific T cells present during the induction, onset, and recovery from disease. They identified two distinct subsets of T cells, or clonotypes, soon after immunization and prior to disease onset: BV8S2/BJ2S7 and BV16/BJ2S5.

The BV8S2/BJ2S7 clonotype was found in far greater excess, disappeared with disease recovery, and was found to transfer disease to other healthy mice.

The second clonotype, BV16/BJ2S5, persisted following recovery, consistent with the hypothesis that the other, BV8S2/BJ2S7 T cell clonotype, is the driver of disease and necessary for EAE/MS persistence. The identification of this T cell subset suggests that these cells may be critical targets valuable to the design of therapies for autoimmune diseases such as MS.

AUTHOR CONTACT: Eli E. Sercarz Torrey Pines Institute for Molecular Studies, San Diego, California, USA. Phone: (858) 455-3824; Fax: (858) 455-3715; E-mail: esercarz@tpims.org


'"/>




Related medicine news :

1. Asbestos Exposure Associated With An Increased Risk For Autoimmune Disease
2. New Oral Medication That Could Arrest Autoimmune Diseases In its early Stages
3. Autoimmune disorder caused due to mutation in cryopyrin protein
4. Gold Therapy- A Potential Treatment For Autoimmune Diseases
5. Autoimmune Diseases – Newer Preventive Measure
6. Autoimmune disorders studied in detail by U-M researchers.
7. Understanding Autoimmune Disease
8. A Single Biological Mechanism Behind Several Autoimmune Disorders
9. Researchers Discover New Molecular Path to Fight Autoimmune Diseases
10. Autoimmune Diseases can Be Prevented by Green Tea
11. New Therapeutic Approach for Autoimmune and Inflammatory Diseases
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/19/2017)... ... 2017 , ... Connecticut Dermatology Group (CDG) is proud and excited to welcome ... Dr. Kim brings an extensive background in cutting-edge dermatology care and research to ... welcome back Dr. Kim to the CDG team” said President and Managing Partner Dr. ...
(Date:1/19/2017)... ... , ... Sales Focus Inc. (SFI), a Maryland-based sales outsourcing company, announced today ... past 20 years SFI has been recognized as the world’s leader in Intelligent Sales ... the US market. The new clients include: Panacea Pro, Campseekers, Contentmart, Stress Pal, ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Infinity® Massage Chairs ... plan and implement new sales and marketing strategies. Grover comes with a total of ... 5 and a half years as Executive Vice President of Direct Sales at Traeger® ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... of Proctology) announced today the opening of 3 medical offices specializing specifically ... Hemorrhoids Center of Los Angeles (Beverly Hills), Hemorrhoids Center of Newport Beach, ...
(Date:1/18/2017)... ... 18, 2017 , ... A recent video posting of a new fidget product ... of fidgeting to relieve stress and anxiety. No one was more surprised than ... had just completed a successful Kickstarter campaign raising $67,000 on the popular crowdfunding platform. ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... PHILADELPHIA , Jan. 18, 2017 The Philadelphia ... three companies developing medical devices for children. The Consortium ... to receive seed grants of $50,000 each. The ... amplifies weak nerve signals, a hand-operated rapid blood delivery system ... ears in babies. ...
(Date:1/18/2017)... , Jan. 18, 2017   Regenicin, Inc. ... biotechnology company specializing in the development and commercialization of ... tissues and organs, recently reported the Company,s operating results ... 2017. As the Company described in its ... a year of substantial accomplishments. The Company,s contract laboratory ...
(Date:1/18/2017)... 2017  Dermata Therapeutics, LLC, a biotechnology company ... variety of dermatological diseases, announces dosing the first ... Phase 2 acne rosacea study. DMT210 is a ... cytokines in the skin responsible for the inflammation ... This clinical trial, DMT210-003, is a 12-week, ...
Breaking Medicine Technology: